EOI for the @MOGA_ORG Mentorship Program #NOMP25 closing soon! We invite all 🇦🇺 med onc consultants and trainees to sign up. Benefits include networking outside your workplace, support to address career navigation, wellbeing and burnout. 🔗: shorturl.at/pS3Fg

Our early-phase trial of DEP-SN38, a poly-lysine dendrimer–conjugated SN38 platform, is now published @ascocancer.bsky.social #JCO @oncocook.bsky.social 💡As TOP1I ADC programs rise, there's growing interest in better payload delivery—and not just through antibodies. Can dendrimers assist? ⬇️🧵

One week until the inaugural #ESMOTATAsia25 🤩 I'm looking forward to joining global drug development experts in🍜🇭🇰 + sharing insights on dose optimisation of novel combinations 🗓️ Saturday 19 July 2pm. @myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social

Live Webinar @cmri_aus Unlocking Proteomics for Smarter ADC Development 🗓 Thurs 26 June 2025 | 4–5:15 PM AEST Join us on mass spec-based proteomics to accelerate and refine ADC development. events.teams.microsoft.com/event/271eed...

Come work with us St Vincent's Private Hospital Sydney! 🏥🧬🩺 Position for oncology / hematology career medical officer now open: svha.wd3.myworkdayjobs.com/en-GB/SVHA_S...

Atezolizumab did not improve clinical outcomes in patients with locally advanced squamous cell carcinoma of the head and neck at high risk of disease progression after multimodal definitive treatment. https://ja.ma/4jVjthY

AACR12 vs AACR25 - Jia Liu @jiajennyliu.bsky.social @theaacr.bsky.social @kinghorncancer.bsky.social oncodaily.com/blog/jia-liu... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AACR25 #AACR12

Drs. Michael Cecchini and @jiajennyliu.bsky.social co-chair an exciting symposium #AACR25 on new antibody drug conjugate (ADC) and immuno-oncology focused approaches to treating #cancer. @theaacr.bsky.social

A powerful conclusion to the opening ceremony of #AACR25 - cancer research saves lives 💚 @theaacr.bsky.social

Incredible #AACR25 #WICR leadership workshop on now on building resilience in science 🔬🧬💃 loving the networking and open discussions + 🥗🥪🍪 @theaacr.bsky.social @hfpconsulting.bsky.social

Great workshop and talk #YingYuan @mdanderson.bsky.social @fda.gov on 🔧 backfill strategies in early phase trials including novel BARD covariate-adaptive randomisation strategies allowing dose escalation, backfill and randomisation data to ⏫ efficiency of 🧬 trials #ProjectOptimus #AACR25

It’s that time of the year again… Getting ready to 🦹‍♀️timeshift - heading to @AACR #AACR25 and looking forward to connecting with 🌍 colleagues very soon!

Sacituzumab + Pembro in ASCENT04 improves Progression Free Survival in Patients With Previously Untreated PD-L1 Metastatic Triple-Negative Breast Cancer #bcsm www.gilead.com/news/news-de... @oncoalert.bsky.social

Looking forward to the @theaacr.bsky.social Annual Meeting taking place in #Chicago beginning later this week for the latest/greatest in #cancerresearch. Follow the #AACR25 tag and the Social Media Ambassador team for insights throughout the Meeting.

@theaacr.bsky.social #AACR25 meeting less than 2 wks away! I’m looking forward to the clinical trials sessions in this years' meeting 'Unifying Cancer Science and Medicine: a continuum for innovation for impact' 🤝 #PatriciaLorusso Overview of 37 oral abstracts ⬇️

🚨New 2 min🎞️summarising step-by-step plan to address fear of #cancer recurrence in clinical practice. Watch youtu.be/cr_3KEOTAv8?... Read the 📰 👉 link.springer.com/article/10.1... Listen to the podcast w/ @bogda-koczwara.bsky.social & Sophie Lebel🎙️ oncologynews.com.au/clinical-foc... Explanatory🧵👇

Looking forward to joining this stellar team on important webinar on #cancersurvivorship #oncsky 📅 Date: Tuesday, 27 May 2025 ⏰ Time: 7:00-8:30PM (UTC+10:00) Canberra, Melbourne, Sydney ➡️ Register today - lnkd.in/gw5GJSZk

Early ✈️ for @sahmriAU South Australian Cancer Research Network planning day representing NSW ➡️ showcasing @NECTANSW as example of successful statewide trials network to facilitate 🔬🏥🧬🧑‍🧑‍🧒‍🧒 Our 28 March Drug Dev Day around the corner! Reg: oncologydrugdevelopment.weebly.com/registration...

My 6 yo 👧🏻 had a melt down at swimming class, when she waited patiently for 40min to join her favourite teacher’s class only to be told it was over booked and she had make up teacher. I told her about the time I desperately wanted to do a research project in obstretrics - IVF was so cool 🧫🔬➡️👶🏻 🧵➡️

Amen 🙏. @thelancet.bsky.social #medsky #oncsky

Thanks for this collaborative global 🌍 effort! Contemporaneous review about state of play of drug development, precision oncology & early phase clinical trials in oncology. @jiajennyliu.bsky.social @oncocook.bsky.social @mcrcnews.bsky.social

@ascocancer.bsky.social welcome to 🦋! We are so glad you are finally here 🙌 #medsky #oncsky

Cannot think of a better candidate for AACR Board of Directors than the incredible Tim Yap - clinician scientist @mdanderson.bsky.social, drug development guru and synthetic lethality 👑. Cast your vote @theaacr.bsky.social: www.aacr.org/professional... #onsky #medsky #drugdevelopment

Oncology drug development 🧬💊 has come a long way, but the system is riddled with inefficiency, inequity and costs are ⏫. Excited to share our 🌎 review article in press in JCO @ascocancer.bsky.social highlighting role of early phase consortia in tackling these challenges: 🧵 1) #medsky #oncsky

Cardiorespiratory fitness overrides BMI for association with reduced all-cause and cardiovascular mortality, results from a systematic review of 20 studies bjsm.bmj.com/content/earl... www.washingtonpost.com/wellness/202...

Excited to share our perspective on cancer therapy response models, "The Hallmarks of Predictive Oncology" doi.org/10.1158/2159... We propose and discuss seven "hallmarks" necessary for clinical adoption of AI models. @bhaibeka.bsky.social #Oncsky #CompBio #AI #ML #PrecisionOncology

Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations www.nature.com/articles/s41...

🌟 Thrilled to Share My Latest Blog with AACR - American Association of Cancer Research ⭐️Creating a World Where Precision Oncology is a Reality for All ⭐️2024 was a terrific year for precision oncology & looking forward for more advances in 2025 @theaacr.bsky.social www.aacr.org/blog/2024/12...

As an oncologist, I get constant reminders that holidays are joyful & meaningful milestones, but not every yr & not for everyone. If you are with #grief, I hope this will remind you that you belong to something vast & are not alone. #MedSky #OncSky #LongCovid www.nytimes.com/2024/12/20/s...

Cancer does not discriminate. Neither should clinical trials. Proud to work with 🌟 team at @kinghorncancer.bsky.social to provide trial options for incredible people like Leanne ❤️ www.abc.net.au/news/2024-12... #oncsky #medsky

Insightful thing that Miss 6 👧🏻 has told me about my job in oncology “I hate that you ✈️ so much for work. But I know you do it to 🗣️ 🌏 about new 💊 and if it works your patients can live to 99/100!!!” The next generation knows best what the bar should be for new drugs in oncology!! #onsky #medsky

Thanks @herbalgill.bsky.social for sharing and great to raise awareness of importance of survivorship needs for cancer patients and strategies to manage FCR through screening and stepped care interventions on 🇦🇺 📻 Paper led by AProf Ben Smith here: pubmed.ncbi.nlm.nih.gov/39375279/

Happy 🦋 thanksgiving from @kinghorncancer.bsky.social Phase 1 Dream team. So grateful to work with this incredible team of humans to bring novel therapies to benefit patients in need. Eg of tumor response on a phase 1 trial here. 🌟🌟🌟 📉 The future is 🌈 #oncsky #medsky #thanksgiving

🧑‍🔬🏛️👩‍⚕️ Lots of our #CancerImmunology community now here 🦋, including @jimallisonphd.bsky.social 🏅! #AcademicSky #ImmunoSky #OncSky #StarterPack 1 is already full 🙌, so starting a another one. Let's continue growing! - Pack 1️⃣: go.bsky.app/PRdmHCP - Pack 2️⃣: go.bsky.app/93eqJbs

Welcome to @bsky.app @arndtvogel.bsky.social ! 💙 Still waiting for ESMO and ASCO! 🦋

Wow—one of the most impressive bench-to-bedside stories you’re ever going to see out today @Nature Spatial proteomics of potentially fatal toxic epidermal necrolysis/Stevens-Johnson Syndrome drug reactions identifies JAK/STAT pathway inhibition as effective therapy! www.nature.com/articles/s41...

www.inc.com/jeff-haden/w...

Beyond the blood: expanding CAR-T cell therapy to solid tumors Posting the most exciting recent cancer literature on BlueSky🦋! @natureportfolio.bsky.social @oncoalert.bsky.social #cancer #science #oncology www.nature.com/articles/s41...

"I want to make a difference in the cancer space, and I have a limited amount of time and energy available to do it. Wading through uncurated content, hostile posts, & medical misinformation isn’t how I want to spend my days." #oncSky #canSky 💙 migration #eXodus www.statnews.com/2024/11/22/t...

Welcome to Bluesky @theaacr.bsky.social! Abstract submissions for #AACR25 (April 25-30, Chicago), chaired by Lillian L. Siu and Matthew G. Vander Heiden close 26 Nov, and clinical trial abstracts LBA close 16 Jan. Excited to serve on the clinical trials committee for 2025 🌟 bit.ly/3YScdu8

❗The power of mentorship in combating burnout among oncology professionals. onlinelibrary.wiley.com/doi/10.1111/... Pleased to share with 🦋 🌏 the results of our #NOMP23 National Oncology Mentorship Program co-led by Udit Nindra, endorsed by MOGA 🇦🇺: #OncSky #WellbeingMedSky #MedSky 🧵 (1/6)

👋 💙🦋 1200 followers in 4 days. Grateful for this open platform and ease of connecting with new friends around the 🌏! About me: I am a 👩🏻‍⚕️👩🏻‍🔬 med onc clinician researcher working in early phase trials/drug development from 🦘🇦🇺🐨. Career goal: patient centric drug development. 💊🧬 Hobbies: 💃🏻🏋🏻‍♀️🧁

“To better understand how a living cell functions and adapts to changing conditions we need systems level perspective and experimentation for which proteomics is the essential technology.” Prof Ruedi Aebersold. ProCan MultiOmics conference kicking off with King of proteomics 🌟

🔥 In Press🔥: Our updated review of immunotherapy in cutaneous oncology just published in EJC. Congrats Dr James Pham, our former Onco Derm Phase 1 trainee at SVH for leading this effort! ☀️🌟 www.ejcancer.com/article/S095...

Thank you @liangrhea.bsky.social for getting me here, great to see increasing friends joining! Other helpful tips: 💙 Joining starter packs helps those with common interests / passions to find/follow you. e.g. oncology: bsky.app/starter-pack... wellbeing: bsky.app/starter-pack....

I've added few new people to the #WellbeingMedSky starter pack. A place to connect with people who want to improve the wellbeing and working lives of health professionals. If ever there was a time to prioritise this, It's now. go.bsky.app/NqFoKDt

Dion Forstner @thefortrans.bsky.social is here on 🦋! Radiation oncologist, President of COSA (Clinical Oncological Society of Australia) and a constant advocate for everything good- patient care, good culture, diversity, clinical innovation.

Let's be clear, Wellbeing in healthcare is not fluffy stuff. It's about workload, staffing, systems & culture. It's about valuing our own needs, modelling humanity & vulnerability, Creating spaces where people feel able to be authentic & ask for help. Wellbeing must be a priority. #MedSky

You know when it has become official when... Control X Control V 🦋

Very appropriate that people are moving to @bsky.app given the dumpster fire that #twitterx appears to become. Let’s do this! www.theguardian.com/technology/2...